A phase II trial of a selective c-Met inhibitor tivantinib (ARQ 197) monotherapy as a second- or third-line therapy in the patients with metastatic gastric cancer

Author： Kang Yoon-Koo   Muro Kei   Ryu Min-Hee   Yasui Hirofumi   Nishina Tomohiro   Ryoo Baek-Yeol   Kamiya Yukimasa   Akinaga Shiro   Boku Narikazu  

Publisher： Springer Publishing Company

ISSN： 0167-6997

Source： Investigational New Drugs, Vol.32, Iss.2, 2014-04, pp. : 355-361

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Related content

Synergistic Activity of the c-Met and Tubulin Inhibitor Tivantinib (ARQ197) with Pemetrexed in Mesothelioma Cells

By  

Current Drug Targets, Vol. 15, Iss. 14, 2014-12 ,pp. : 1331-1340

Bentham Science Publishers

Access to resources Recommend Favorite

Phase II trial of pemetrexed as second-line therapy in patients with metastatic urothelial carcinoma

By Galsky Matthew   Mironov Svetlana   Iasonos Alexia   Scattergood Joseph   Boyle Mary   Bajorin Dean  

Investigational New Drugs, Vol. 25, Iss. 3, 2007-06 ,pp. : 265-270

Springer Publishing Company

Access to resources Recommend Favorite

A phase II study of sabarubicin (MEN-10755) as second line therapy in patients with locally advanced or metastatic platinum/taxane resistant ovarian cancer

By Caponigro Francesco   Willemse Pax   Sorio Roberto   Floquet Anne   van Belle Simon   Demol Jan   Tambaro Rosa   Comandini Alessandro   Capriati Angela   Adank Sabine   Wanders Jantien  

Investigational New Drugs, Vol. 23, Iss. 1, 2005-01 ,pp. : 85-89

Springer Publishing Company

Access to resources Recommend Favorite

A phase II study of cell cycle inhibitor UCN-01 in patients with metastatic melanoma: a California Cancer Consortium trial

By Li Tianhong  

Investigational New Drugs, Vol. 30, Iss. 2, 2012-04 ,pp. : 741-748

Springer Publishing Company

Access to resources Recommend Favorite

Capecitabine monotherapy is an effective and well tolerated first-line treatment for patients with advanced or metastatic gastric cancer

By  

Inpharma, Vol. 1, Iss. 1457, 2004-01 ,pp. : 17-18

Adis International

Access to resources Recommend Favorite